Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Professor’s research part of major global programme
2011-04-04

 

Prof. Zakkie Pretorius, professor in Plant Pathology in the Department of Plant Sciences at our university

Research by Zakkie Pretorius, professor in Plant Pathology in the Department of Plant Sciences at our university, has become part of Phase II of a mayor global project to combat deadly strains of a wheat pathogen that poses a threat to global food security.

Prof. Pretorius focuses on the identification of resistance in wheat to the stem rust disease and will assist breeders and geneticists in the accurate phenotyping of international breeding lines and mapping populations. In addition, Prof. Pretorius will support scientists from Africa with critical skills development through training programmes. During Phase I, which ends in 2011, he was involved in pathogen surveillance in Southern Africa and South Asia.
 
The Department of International Development (DFID) in the United Kingdom and the Bill and Melinda Gates Foundation will invest $40 million over the next five years in the global project led by the Cornell University. The project is aimed at combating deadly strains of Ug99, an evolving wheat pathogen that is a dangerous threat to global food security, especially in the poorest nations. 
 
The Cornell University said in a statement, the grant made to the Durable Rust Resistance in Wheat (DRRW) project at Cornell will support efforts to identify new stem-rust resistant genes in wheat, improve surveillance, and multiply and distribute rust-resistant wheat seed to farmers and their families.
 
Researchers worldwide will be able to play an increasingly vital role in protecting wheat fields from dangerous new forms of stem rust, particularly in countries whose people can ill afford the economic impact of damage to this vital crop.
 
The Ug99 strain was discovered in Kenya in 1998, but are now also threatening major wheat-growing areas of Southern and Eastern Africa, the Central Asian Republics, the Caucasus, the Indian subcontinent, South America, Australia and North America.
 
Prof. Pretorius was responsible for the first description of this strain in 1999.
 
Among Cornell’s partners are national research centres in Kenya and Ethiopia, and scientists at two international agricultural research centres that focus on wheat, the Mexico-based International Maize and Wheat Improvement Center (known by its Spanish acronym as CIMMYT), and the International Center  for Agricultural Research in the Dry Areas (ICARDA), in Syria. Advanced research laboratories in the United States, Canada, China, Australia, Denmark and South Africa also collaborate on the project. The DRRW project now involves more than 20 leading universities and research institutes throughout the world, and scientists and farmers from more than 40 countries.


Media Release
28 March 2011
Issued by: Lacea Loader
Director: Strategic Communication
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: news@ufs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept